Tatsis Ourania 4

What Happened

• Ourania Tatsis, a director of Odyssey Therapeutics (ODTX), was granted a derivative equity award covering 27,393 shares on May 7, 2026. The reported acquisition price is $0.00 (no cash exchanged at grant). The award is recorded as a derivative security (an option per the footnote) rather than an immediate stock purchase.

Key Details

• Transaction date: 2026-05-07; Form 4 filed: 2026-05-11 (filed within the two-business-day reporting window).
• Instrument: Derivative equity award (option) covering 27,393 shares; reported price $0.00.
• Vesting: Footnote states the option will vest in full on May 7, 2027, subject to continued service.
• Shares owned following the transaction: not specified in the provided excerpt.
• Filing timeliness: Timely (filed on 2026-05-11 for a 2026-05-07 transaction).

Context

• This was a compensation grant to a director, not an open-market purchase or sale; it does not immediately change Tatsis’s cash position or create tradable shares until vested/exercised. Such grants are common for board compensation and reflect pending future ownership only if vesting conditions are met.